146 results on '"Marsh, Henry C."'
Search Results
2. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
3. Neuronal Protection in Stroke by an sLe$^x$-Glycosylated Complement Inhibitory Protein
4. Dual targeting of mast cells and TSLP with a bispecific antibody
5. Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4
6. Supplementary Table 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
7. Supplementary Figure 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
8. Data from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
9. FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome
10. Complement activation is critical for placental ischemia-induced hypertension in the rat
11. Comparison of Complement Activity in Adult and Preterm Sheep Serum
12. Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
13. Abstract 1865: Simultaneous de-repression of innate and adaptive immune responses through dual targeting of ILT4 and PD(L)-1 with bispecific antibodies
14. The Partly Folded Back Solution Structure Arrangement of the 30 SCR Domains in Human Complement Receptor Type 1 (CR1) Permits Access to its C3b and C4b Ligands
15. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice
16. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells
17. Eradication of Non-T Cell-Inflamed Tumors by in Situ Immunomodulation with PD-L1 Blockade
18. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
19. Abstract P5-04-03: Conversion of non-T cell-inflamed triple-negative breast cancer byin situimmunomodulation of induced intratumoral cross-presenting dendritic cells
20. Co-administration of a CpG adjuvant (VaxImmuneTM, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice
21. Pre-clinical evaluation of an sLex-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke
22. Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology
23. Abstract 3217: Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA
24. Abstract 2392: CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1
25. Abstract 1555: Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases
26. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
27. Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models
28. Abstract 5624: Development of novel bispecific immune modulating antibodies
29. Abstract B194: Identification and characterization of monoclonal antibodies targeting the Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinases
30. Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules
31. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy
32. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
33. Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
34. Abstract 4866: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy
35. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
36. Abstract 253: Synergistic antitumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site
37. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
38. Abstract 2649: Development of an antibody-drug conjugate targeting TIM-1 for the treatment of ovarian and renal cell carcinoma
39. Comparison of Complement Activity in Adult and Preterm Sheep Serum
40. Soluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy
41. Comparative Pharmacokinetics of the Complement Inhibitor CDX‐1135
42. Radioprotective and Radiomitigative Efficacy of Flt3 Ligand in a Murine Model of Acute Radiation Injury.
43. Enhancement of the activity of the complement inhibitor CDX‐1135 by a monoclonal antibody
44. Development of an assay of neutralizing antibodies to the complement inhibitor CDX‐1135
45. Abstract 4560: Anti-tumor activity of a fully human anti-CD27 monoclonal antibody in a transgenic mouse model
46. Preclinical evaluation of the neuroprotective effect of soluble complement receptor Type 1 in a nonhuman primate model of reperfused stroke
47. Synthesis and Complement Inhibitory Activity of B/C/D-Ring Analogues of the Fungal Metabolite 6,7-Diformyl-3‘,4‘,4a‘,5‘,6‘,7‘,8‘,8a‘-octahydro-4,6‘,7‘-trihydroxy- 2‘,5‘,5‘,8a‘-tetramethylspiro[1‘(2‘H)-naphthalene-2(3H)-benzofuran]
48. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis
49. A direct comparison of complement inhibitory capacities of the GPI- and transmembrane forms of mouse DAF to mouse Crry and human rsCR1
50. Characterization of N‐linked oligosaccharides bearing sialyl Lewis x moieties on an alternatively glycosylated form of soluble complement receptor type 1 (sCR1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.